Business Description
Vitrolife AB
ISIN : SE0011205202
Compare
Compare
Traded in other countries / regions
VITR.Sweden0YAY.UKVTFN.GermanyVTRLY.USA IPO Date
2014-06-17Description
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.45 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Interest Coverage | 11.51 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.18 | |||||
| Beneish M-Score | -3.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 31.2 | |||||
| 3-Year FCF Growth Rate | 15 | |||||
| 3-Year Book Growth Rate | 71.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.03 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.47 | |||||
| 9-Day RSI | 61.47 | |||||
| 14-Day RSI | 54.01 | |||||
| 6-1 Month Momentum % | 29.06 | |||||
| 12-1 Month Momentum % | 17.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.91 | |||||
| Quick Ratio | 2.36 | |||||
| Cash Ratio | 1.28 | |||||
| Days Inventory | 99.85 | |||||
| Days Sales Outstanding | 57.1 | |||||
| Days Payable | 41.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.45 | |||||
| Forward Dividend Yield % | 0.45 | |||||
| 5-Year Yield-on-Cost % | 0.45 | |||||
| 3-Year Average Share Buyback Ratio | -7.7 | |||||
| Shareholder Yield % | 0.89 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.16 | |||||
| Operating Margin % | 21.69 | |||||
| Net Margin % | -107.06 | |||||
| FCF Margin % | 21.74 | |||||
| ROE % | -27.33 | |||||
| ROA % | -21.59 | |||||
| ROIC % | 4.88 | |||||
| ROC (Joel Greenblatt) % | -401.37 | |||||
| ROCE % | -21.08 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 45.89 | |||||
| Shiller PE Ratio | 7477.33 | |||||
| PS Ratio | 8.29 | |||||
| PB Ratio | 2.24 | |||||
| Price-to-Free-Cash-Flow | 38.09 | |||||
| Price-to-Operating-Cash-Flow | 36.31 | |||||
| EV-to-EBIT | -8.53 | |||||
| EV-to-EBITDA | -8.53 | |||||
| EV-to-Revenue | 8.6 | |||||
| EV-to-FCF | 39.55 | |||||
| Price-to-Projected-FCF | 1.62 | |||||
| Price-to-Median-PS-Value | 0.64 | |||||
| Earnings Yield (Greenblatt) % | -11.72 | |||||
| FCF Yield % | 2.63 | |||||
| Forward Rate of Return (Yacktman) % | 5.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vitrolife AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 314.946 | ||
| EPS (TTM) (€) | -2.515 | ||
| Beta | -0.4 | ||
| Volatility % | 47.43 | ||
| 14-Day RSI | 54.01 | ||
| 14-Day ATR (€) | 0.271534 | ||
| 20-Day SMA (€) | 18.653 | ||
| 12-1 Month Momentum % | 17.66 | ||
| 52-Week Range (€) | 13.48 - 24 | ||
| Shares Outstanding (Mil) | 135.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vitrolife AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vitrolife AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vitrolife AB Frequently Asked Questions
What is Vitrolife AB(STU:VTFN)'s stock price today?
The current price of STU:VTFN is €19.09. The 52 week high of STU:VTFN is €24.00 and 52 week low is €13.48.
When is next earnings date of Vitrolife AB(STU:VTFN)?
The next earnings date of Vitrolife AB(STU:VTFN) is 2025-01-30.
Does Vitrolife AB(STU:VTFN) pay dividends? If so, how much?
The Dividend Yield %  of Vitrolife AB(STU:VTFN) is 0.45% (As of Today), Highest Dividend Payout Ratio of Vitrolife AB(STU:VTFN) was 0.27. The lowest was 0.19. And the median was 0.25. The  Forward Dividend Yield % of Vitrolife AB(STU:VTFN) is 0.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers